This study will be a single arm multicenter Phase II open-label, dose escalation study of asciminib in patients with CML-CP without T315I mutation who have had 1 prior TKIs for which they did not respond to treatment or were intolerant to treatment.
1 Primary · 8 Secondary · Reporting Duration: Baseline up to 3, 6, 18, and 24 months
Experimental Treatment
92 Total Participants · 1 Treatment Group
Primary Treatment: Asciminib · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: